Bristol Myers Squibb Co 8-K Filing
Ticker: CELG-RI · Form: 8-K · Filed: Nov 3, 2025 · CIK: 14272
| Field | Detail |
|---|---|
| Company | Bristol Myers Squibb Co (CELG-RI) |
| Form Type | 8-K |
| Filed Date | Nov 3, 2025 |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.10, $7 b |
| Sentiment | neutral |
Sentiment: neutral
FAQ
What type of filing is this?
This is a 8-K filing submitted by Bristol Myers Squibb Co (ticker: CELG-RI) to the SEC on Nov 3, 2025.
What are the key financial figures in this filing?
Key dollar amounts include: $0.10 (ange on which registered Common Stock, $0.10 Par Value BMY New York Stock Exchan); $7 b (or an aggregate purchase price of up to $7 billion, subject to the Pool 1 Maximum an).
How long is this filing?
Bristol Myers Squibb Co's 8-K filing is 2 pages with approximately 643 words. Estimated reading time is 3 minutes.
Where can I view the full 8-K filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 643 words · 3 min read · ~2 pages · Grade level 11.9 · Accepted 2025-11-03 06:09:11
Key Financial Figures
- $0.10 — ange on which registered Common Stock, $0.10 Par Value BMY New York Stock Exchan
- $7 b — or an aggregate purchase price of up to $7 billion, subject to the Pool 1 Maximum an
Filing Documents
- ef20058056_8k.htm (8-K) — 36KB
- ef20058056_ex99-1.htm (EX-99.1) — 112KB
- image0.jpg (GRAPHIC) — 327KB
- 0001140361-25-040066.txt ( ) — 779KB
- bmy-20251103.xsd (EX-101.SCH) — 4KB
- bmy-20251103_def.xml (EX-101.DEF) — 18KB
- bmy-20251103_lab.xml (EX-101.LAB) — 26KB
- bmy-20251103_pre.xml (EX-101.PRE) — 20KB
- ef20058056_8k_htm.xml (XML) — 7KB
01
Item 8.01 Other Events. On November 3, 2025, Bristol-Myers Squibb Company ("Bristol Myers Squibb" or the "Company") issued a press release announcing the commencement of cash tender offers (the "Offers") to purchase certain of its outstanding notes for an aggregate purchase price of up to $7 billion, subject to the Pool 1 Maximum and Pool 2 Maximum as described in the press release. The Offers are subject to the terms and conditions described in the Company's Offer to Purchase dated November 3, 2025 (as it may be amended or supplemented from time to time, the "Offer to Purchase"), which sets forth a detailed description of the Offers. A copy of the Company's press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. This Current Report on Form 8-K (including the exhibits attached hereto) is neither an offer to purchase nor a solicitation of an offer to sell any securities. The Offers are made only by, and pursuant to the terms of, the Offer to Purchase. The Offers do not constitute an offer to buy or the solicitation of an offer to sell the notes described herein in any jurisdiction in which such offer or solicitation is unlawful. The Offers are void in all jurisdictions where they are prohibited.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits The following exhibits are included as part of this Current Report on Form 8-K: Exhibit No. Description 99.1 Press release of Bristol-Myers Squibb Company dated November 3, 2025 104 The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRISTOL-MYERS SQUIBB COMPANY Dated: November 3, 2025 By: /s/ Amy Fallone Name: Amy Fallone Title: Senior Vice President and Corporate Secretary